잠시만 기다려 주세요. 로딩중입니다.

Colitis and Crohn’s Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease

Intestinal Research 2020년 18권 4호 p.355 ~ 378
Sood Ajit, Ahuja Vineet, Midha Vandana, Sinha Saroj Kant, Pai C. Ganesh, Kedia Saurabh, Mehta Varun, Bopanna Sawan, Abraham Philip, Banerjee Rupa,
소속 상세정보
 ( Sood Ajit ) - Dayanand Medical College and Hospital Department of Gastroentrology
 ( Ahuja Vineet ) - All India Institute of Medical Sciences Department of Gastroenterology
 ( Midha Vandana ) - Dayanand Medical College and Hospital Department of Internal Medicine
 ( Sinha Saroj Kant ) - Postgraduate Institute of Medical Education and Research Department of Gastroenterology
 ( Pai C. Ganesh ) - Kasturba Medical College Department of Gastroenterology
 ( Kedia Saurabh ) - All India Institute of Medical Sciences Department of Gastroenterology
 ( Mehta Varun ) - Dayanand Medical College and Hospital Department of Gastroentrology
 ( Bopanna Sawan ) - Fortis Hospital
 ( Abraham Philip ) - P. D. Hinduja Hospital and Medical Research Centre
 ( Banerjee Rupa ) - Asian Institute of Gastroenterology

Abstract


Despite several recent advances in therapy in inflammatory bowel disease (IBD), 5-aminosalicylic acid (5-ASA) therapy has retained its place especially in ulcerative colitis. This consensus on 5-ASA is obtained through a modified Delphi process, and includes guiding statements and recommendations based on literature evidence (randomized trials, and observational studies), clinical practice, and expert opinion on use of 5-ASA in IBD by Indian gastroenterologists. The aim is to aid practitioners in selecting appropriate treatment strategies and facilitate optimal use of 5-ASA in patients with IBD.

키워드

Inflammatory bowel disease; 5-Aminosalicylic acid; Crohn disease; Colitis, ulcerative; Mesalamine

원문 및 링크아웃 정보

 

등재저널 정보

KCI
KoreaMed
KAMS